In high-dose direct-compression tablet manufacture for companion animal lead and mercury chelation protocols, sodium dimercaptosuccinate veterinary grade API is first de-agglomerated through a 500 µm mesh screen to break loose aggregates. High-shear mixing is avoided because the two free sulfhydryl groups are oxidation-sensitive and because the crystalline API exhibits a brittle fracture tendency under compaction. A representative evaluation matrix places the API load between 60% w/w and 80% w/w, with microcrystalline cellulose PH-102 as a brittle-fill binder, crospovidone as a disintegrant at 2–4% w/w, and magnesium stearate at 0.5–1.0% w/w. A compaction simulator operating at punch tip velocities of 100–300 mm/s and dwell times of 20–40 ms is used to map compressibility before scale-up; tablet tensile strength below 1.5 MPa at 0.85 solid fraction predicts capping in production. On a rotary press with B-tooling, precompression at 3–6 kN and main compression at 12–20 kN are evaluated to reduce capping, which appears when the API load exceeds 70% w/w and ejection force rises above 700 N. If the die table relative humidity exceeds 60%, the powder can pick up surface moisture and stick to upper punches; the corrective action is dehumidification rather than additional lubricant because excess magnesium stearate above 1.5% w/w delays disintegration and increases dissolution variability.

Finished tablets are tested for content uniformity according to USP <905> and for dissolution according to USP <711>. The dissolution medium is purged with nitrogen because free-thiol oxidation during the test can produce a falsely low spectrophotometric reading. The tablet formulation is intended for rapid upper-gastrointestinal release; no enteric coating is applied because delayed release conflicts with the clinical need for fast chelation onset in acute toxicosis. Packaging is specified with aluminum blister lidding and an Aclar or cold-form foil base, and a desiccant is included when stability data show that water activity above 0.3 aw accelerates disulfide formation in the API. Batch-to-batch moisture of the API is controlled by Karl Fischer titration to ≤2.0% w/w before blending; a higher moisture value shifts the compaction profile and may move the tablet from acceptable capping resistance into an over-compressed brittle core. In-process controls align with 21 CFR 211.110 for sampling and testing of in-process materials.

What Limits Sterile Filtration Throughput for DMSA Sodium Injection Lines?

Sterile filtration of a sodium dimercaptosuccinate injection intermediate is constrained by oxidative degradation during hold time rather than by mechanical fouling. The API dissolves in Water for Injection with sodium chloride or mannitol for isotonicity; the solution is maintained under a nitrogen overlay until dissolved oxygen is reduced to ≤1.0 mg/L. Filtration is performed through a 0.22 µm polyethersulfone or polyvinylidene fluoride membrane, with membrane surface area selected to maintain a pressure differential below 0.8 bar at 20°C. Because unbound sulfhydryl groups can react with trace transition metals in stainless steel surfaces, product-contact materials are passivated and the holding vessel is tested for extractable iron; transition-metal contamination exceeding 0.1 mg/L can promote disulfide dimer formation, visible as slight turbidity after sterile filtration. Filter bacterial retention compliance is confirmed by ASTM F838-20 for sterilizing-grade membranes, and initial filtrate discard of 5–10 L per 0.5 m² membrane is applied to reduce extractable loading into small-volume parenterals.

Terminal sterilisation by autoclaving at 121°C for 15 min is generally excluded for aqueous DMSA sodium presentations because free-thiol degradation products form under thermal stress; aseptic processing is therefore required. The filled vials are flushed with nitrogen so that headspace oxygen remains below 5.0%, and closure integrity is verified under USP <1207>. Release testing for injectable product includes bacterial endotoxins by USP <85>, sterility by USP <71>, particulate matter by USP <788>, and subvisible particle characterization under USP <787> when solution behavior requires more detailed particle profiling. Published data for ready-to-use aqueous DMSA injection at neutral pH remain limited; when long-term storage is required, a lyophilized presentation is usually selected because the dry cake reduces the free-thiol oxidation rate.

Because sodium dimercaptosuccinate exhibits poor powder flow at a mass-median particle size below 120 µm, hard-gelatin or HPMC capsule filling for equine, avian, and small-mammal dosing uses a densified blend rather than directly filled API powder. The blend is passed through a comill to reduce large agglomerates, and colloidal silicon dioxide is added at 0.5–1.0% w/w to lower interparticle cohesion. Capsule fill weights between 100 mg and 300 mg are produced on a dosator-type encapsulator with powder bed depth maintained between 80 mm and 120 mm; under these conditions, weight variability is held below 2.0% RSD for a well-conditioned blend. When the API is milled below 75 µm without adequate excipient blending, fill weight variability can exceed 3.0% RSD, causing out-of-specification content uniformity against USP <905>. Encapsulation room conditions are controlled at 22 ± 3°C and 35 ± 5% RH because swing-season humidity changes are a common batch-to-batch variability source.

Moisture control is more important in capsules than in tablets because the capsule shell can donate water to the hygroscopic API. The blend moisture is held at 1.5–3.0% w/w; below 1.0% w/w triboelectrification causes powder to cling to the capsule shell wall, while above 4.0% w/w the free sulfhydryl groups show an increased tendency to oxidize during storage. HPMC capsule shells with an equilibrium moisture content below 8% may be preferred over gelatin shells if long-term stability studies show water migration into the API. Dissolution of the filled capsule is tested in deoxygenated medium under USP <711> with a sinker; capsule shell cross-linking or delayed dissolution after storage is evaluated using two-tier dissolution criteria for gelatin capsules.

The following control point matrix lists the compendial method designations applied across the described dosage formats.

Granule Porosity and Sieve Cut Distribution After Low-Shear Wet Granulation

Low-shear wet granulation is used when the finished product must disperse easily in water or be administered as a granule sprinkle on food. The API is dry-blended with pregelatinized starch and microcrystalline cellulose in a planetary mixer at 25–40 rpm for 10–15 min. A binder solution of purified water or 2–5% w/w povidone K-30 is sprayed at 0.4–0.8 L/min per 50 kg batch; endpoint is defined by torque or power-consumption inflection rather than by fixed time because API particle size shifts water absorption rate. Endpoint wet mass moisture is generally between 8% w/w and 12% w/w. Over-wetting above 14% w/w creates dense lumps that require longer drying and reduce granule porosity below 10%; low porosity slows water penetration and extends dispersion time beyond 60 s.

Drying in a fluid-bed dryer at inlet air temperature 45–55°C brings granule moisture to 1.5–2.5% w/w. The dried mass is passed through a conical mill fitted with a 1.0 mm screen at 800–1200 rpm. The final granule fraction is controlled between 250 µm and 710 µm; undersize below 150 µm increases segregation, and oversize above 850 µm impairs content uniformity in unit-dose sachets. Bulk density is controlled between 0.45 g/mL and 0.60 g/mL. For an oral granule, dispersion is confirmed in water at 25°C without foaming; a defoamer is generally not included because the granule should dissolve rapidly without additional surface-active components. Dissolution is evaluated by USP <711> apparatus 2 at 50 rpm, with ascorbic acid 0.1% w/v added to the medium to protect the free thiol groups from oxidation during the run. Published data for DMSA-specific granulation endpoints are limited; the ranges cited here are empirical starting points for hygroscopic thiol APIs and must be verified for a given API lot.

If DMSA Sodium Is Dispersed into a Feed Premix, Segregation Depends on Particle Size Differential and Tribocharging

If sodium dimercaptosuccinate is incorporated into a dry carrier premix for oral administration to a non-food animal or a controlled research colony, the dominant process failure is demixing after the blender rather than poor initial blending. The API is typically milled to a D50 between 50 µm and 100 µm; a lactose monohydrate or corn starch carrier may have a D50 above 150 µm. When the carrier-to-API particle size ratio exceeds 5:1, hopper vibration and discharge can generate fines enrichment, and the assay of the first 10% of material discharged can vary by more than 15% relative to the blend mean. A geometric preblend is therefore prepared with a compatible diluent of particle size close to the API, followed by low-shear tumble blending at 10–15 rpm for 8–12 min. Blend time beyond 20 min may increase tribocharging and reverse the uniformity gain.

The premix is intended only for non-food-animal protocols unless the specific regulatory pathway in the target jurisdiction permits food-producing species and a validated withdrawal period has been assigned; in the United States, any extralabel use determination would be confined to the provisions of 21 CFR 530. If the premix is added to a moist mash or gavage suspension, the use period is limited to 2 h at 25°C unless nitrogen packaging or an oxygen-scavenging system is used because free sulfhydryl groups oxidize rapidly in a wet, oxygenated environment. Transition-metal catalysts such as ferric oxide, copper sulfate, and manganese salts are excluded from the carrier; these ions promote thiol oxidation and can reduce the free-thiol assay below the release limit. Finished premix homogeneity is confirmed by sampling 10–20 points across the blender and by HPLC assay with relative standard deviation not exceeding 5.0%. Dust collector fines are not returned to the blend unless the batch record demonstrates that the fines return step does not create a localized high-potency pocket.

Aqueous Oral Solution Headspace Oxygen and Free-Thiol Potency Loss

An aqueous oral solution of sodium dimercaptosuccinate for companion animals is prepared at concentrations between 10 mg/mL and 50 mg/mL in a buffered, nitrogen-purged medium. The solvent is boiled and cooled under vacuum to reduce dissolved oxygen, then sparged with nitrogen until a dissolved-oxygen probe reads ≤0.5 mg/L. The API is added under a nitrogen blanket and mixed at low shear to avoid vortex air entrainment. The pH is held between 5.0 and 6.5 because free-thiol ionization above pH 7.0 accelerates oxygen uptake and disulfide formation. The finished solution is packaged in amber Type I glass or PET bottles with an oxygen-barrier overpouch and a child-resistant closure. If a multi-dose container includes a preservative, antimicrobial effectiveness testing under USP <51> is required; otherwise the product is restricted to unit-dose or short in-use storage.

Storage at 2–8°C is specified because the solution is not thermostable and cannot be autoclaved. Free-thiol content is measured by an HPLC or iodometric thiol-specific assay during stability; a decrease of more than 5.0% from the release value indicates oxidative degradation beyond the defined shelf-life limit. The oral solution is not used if visible haziness appears after storage because turbidity may indicate disulfide aggregates or trace-metal complexes. Container closure integrity is verified under USP <1207>, and residual oxygen in the headspace is controlled below 5.0% at the time of filling. For oral solutions that are diluted in a feeding syringe immediately before administration, the diluted solution is used within 2 h if not protected from air, because the dilution step introduces additional oxygen.